Table 2.
Poisson regression analysis to evaluate predictors of COVID-19 vaccine breakthrough infection.
| Variable | cRR (95% CI) | p-Value | aRR (95% CI) | p-Value |
|---|---|---|---|---|
| Male sex | 0.575 (0.343–0.965) | 0.037 | 0.430 (0.226–0.816) | 0.010 |
| Previously infected before third wave | 0.785 (0.530–1.162) | 0.227 | 1.688 (0.800–3.559) | 0.169 |
| Infection before the first dose of BBIBP-CorV | 0.889 (0.599–1.319) | 0.560 | ||
| Infection after the first dose of BBIBP-CorV | 1.899 (1.010–3.569) | 0.046 | ||
| Time since the first infection until the third wave | 1.001 (0.998–1.004) | 0.210 | ||
| Nº doses | ||||
| Two doses BBIBP-CorV | Ref. | - | ||
| Two doses BBIBP-CorV plus booster BNT162b2 | 0.874 (0.612–1.247) | 0.459 | ||
| Ab neutralization cPass at 21 days ≥ 60% | 0.615 (0.395–0.958) | 0.032 | 0.621 (0.397–0.971) | 0.037 |
| Ab neutralization cPass at 180 days ≥ 60% | 0.553 (0.373–0. 820) | 0.003 | 0.588 (0.396–0.874) | 0.009 |
| Ab neutralization cPass at 180 days ≥ 90% | 0.579 (0.357–0.938) | 0.026 | 0.598 (0.371–0.964) | 0.035 |
| Elecys Anti-SARS-CoV-2 S at 180 days ≥ 500 | 0.553 (0.353–0.867) | 0.010 | 0.585 (0.373–0.916) | 0.019 |
cRR: crude relative risk; aRR: adjusted relative risk. BBIBP-CorV: inactivated vaccine against SARS-CoV-2 BBIBP-CorV (Sinopharm). BNT162b2: Vaccine ARNm BNT162b2 (Pfizer/BioNTech). The Variables: Ab neutralization cPass at 21 days ≥ 60%, Ab neutralization cPass at 180 days ≥ 60%, Ab neutralization cPass at 180 days ≥ 90% and Elecys anti-SARS-CoV-2 S at 180 days ≥ 500; since they were not independent of each other, they were analyzed individually. The variables were adjusted by sex.